Inventor · disambiguated record
Sandra Berndt
Also filed as: BERNDT SANDRA
12 granted patents·11 pending applications·59 citations·filing 2014–2024
89Inventor score
Top patents by PatentIndex Score
23 records- 0195US11478554B2Antibody drug conjugates (ADCS) having enzymatically cleavable groupsBayer Pharma AG·Filed 2021·Granted Oct 25, 2022·5 cites·20 claims
- 0294US10022453B2Antibody drug conjugates (ADCs) with kinesin spindel protein (KSP)Bayer Pharma AG·Filed 2014·Granted Jul 17, 2018·16 cites·39 claims
- 0392US11427640B1CCR8 antibodies for therapeutic applicationsBAYER IP GMBH·Filed 2021·Granted Aug 30, 2022·4 cites·15 claims
- 0492US11123439B2Antibody drug conjugates (ADCS) and antibody prodrug conjugates (APDCS) with enzymatically cleavable groupsBayer Pharma AG·Filed 2016·Granted Sep 21, 2021·8 cites·51 claims
- 0591US11660351B2Antibody drug conjugates (ADCs) having enzymatically cleavable groupsBayer Pharma AG·Filed 2017·Granted May 30, 2023·5 cites·50 claims
- 0689US11071788B2Antibody drug conjugates of kinesin spindel protein (KSP) inhibitors with antiB7H3-antibodiesBayer Pharma AG·Filed 2016·Granted Jul 27, 2021·6 cites·32 claims
- 0789US10485880B2Antibody-drug conjugates (ADCs) of KSP inhibitors with aglycosylated anti-TWEAKR antibodiesBayer Pharma AG·Filed 2015·Granted Nov 26, 2019·11 cites·29 claims
- 0887US11685714B2Prodrugs of cytotoxic active agents having enzymatically cleavable groupsBayer Pharma AG·Filed 2017·Granted Jun 27, 2023·3 cites·30 claims
- 0980US2025099600A1Active Metabolites of Kinesin Spindle Protein Inhibitor ConjugatesBayer Pharma AG·Filed 2024·Application pending·0 cites
- 1079US2024376218A1Ccr8 antibodies for therapeutic applicationsBAYER AG·Filed 2024·Application pending·0 cites
- 1179US2024400700A1Ccr8 antibodies for therapeutic applicationsBAYER AG·Filed 2024·Application pending·0 cites
- 1275US2023338559A1Antibody drug conjugates (adcs) having enzymatically cleavable groupsBayer Pharma AG·Filed 2023·Application pending·0 cites
- 1372US12065497B2Methods of treatment using CCR8 antibodiesBAYER AG·Filed 2022·Granted Aug 20, 2024·0 cites·17 claims
- 1470US2024043379A1Prodrugs of cytotoxic active agents having enzymatically cleavable groupsBayer Pharma AG·Filed 2023·Application pending·0 cites
- 1568US12144865B2Antibody drug conjugates with enzymatically cleavable groupsBayer Pharma AG·Filed 2021·Granted Nov 19, 2024·0 cites·33 claims
- 1668US11427578B1Substituted pyrrolopyridine-derivativesBayer Pharma AG·Filed 2018·Granted Aug 30, 2022·1 cites·18 claims
- 1765US2022362392A1Specific antibody drug conjugates (adcs) having ksp inhibitorsBayer Pharma AG·Filed 2022·Application pending·0 cites
- 1861US11433140B2Specific antibody drug conjugates (ADCs) having KSP inhibitorsBayer Pharma AG·Filed 2017·Granted Sep 6, 2022·0 cites·9 claims
- 1954US2024174683A1Map4k1 inhibitorsBAYER AG·Filed 2022·Application pending·0 cites
- 2043US2016237160A1Anti-tweakr antibodies and uses thereofBayer Pharma AG·Filed 2014·Application pending·0 cites
- 2140US2022047603A1Substituted pyrrolopyridine-derivativesBAYER AG·Filed 2019·Application pending·0 cites
- 2239US2018318438A1Antibody drug conjugates of kinesin spindel protein (ksp) inhibitors with anti-tweakr-antibodiesBayer Pharma AG·Filed 2016·Application pending·0 cites
- 2336US2018185510A1Antibody drug conjugates of kinesin spindel protein (ksp) inhibitors with anti-b7h3-antibodiesBayer Pharma AG·Filed 2016·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Sandra Berndt files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →